Dns Drugs & Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 3 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.85 Cr
as on 16-11-2024
- Satisfied Charges ₹ 9.22 M
as on 16-11-2024
- Revenue 150.25%
(FY 2023)
- Profit -65.08%
(FY 2023)
- Ebitda -412.72%
(FY 2023)
- Net Worth 7.35%
(FY 2023)
- Total Assets 32.16%
(FY 2023)
About Dns Drugs & Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.85 Cr. The company has closed loans amounting to ₹9.22 M, as per Ministry of Corporate Affairs (MCA) records.
Sneha Jogadia, Shailja Singh, and Stuti serve as directors at the Company.
- CIN/LLPIN
U24299MH2021PTC362408
- Company No.
362408
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Jun 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Dns Drugs & Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sneha Jogadia  | Director | 19-Jun-2021 | Current |
| Shailja Singh | Director | 19-Jun-2021 | Current |
| Stuti | Director | 19-Jun-2021 | Current |
Financial Performance of Dns Drugs & Pharmaceuticals.
Dns Drugs & Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 150.25% increase. The company also saw a substantial fall in profitability, with a 65.08% decrease in profit. The company's net worth moved up by a moderate rise of 7.35%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dns Drugs & Pharmaceuticals?
Unlock access to Dns Drugs & Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 18 Jun 2024 | ₹1.85 Cr | Open |
Others Creation Date: 29 Jun 2023 | ₹9.22 M | Satisfied |
How Many Employees Work at Dns Drugs & Pharmaceuticals?
Dns Drugs & Pharmaceuticals has a workforce of 0 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dns Drugs & Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dns Drugs & Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
